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Purpose: To establish predictive models for late objective aspiration and late patient-reported choking
based on dose–volume parameters and baseline patient and treatment characteristics, for patients with
head and neck cancer undergoing definitive radiotherapy (RT). The impact of electively treated volume on
late aspiration was also investigated.
Methods and material: This prospective cohort is a subsample of 124 survivors from the ARTSCAN study.
Late aspiration was identified with videofluoroscopy, at a minimum of 25 months after the start of RT.
Patient-reported choking was analysed at 12 and 60 months post RT using the EORTC Quality of Life
Module for Head and Neck Cancer 35. Univariable and multivariable analyses were performed to describe
the association between clinical factors and dose–volume descriptors for organs at risk (OARs) and late
dysphagia.
Results: Aspiration was found in 47% of the eligible patients. Mean dose to the middle pharyngeal con-
strictor (MPC), neck dissection post RT and age at randomisation in ARTSCAN were associated to late aspi-
ration. Mean dose to the superior pharyngeal constrictor (SPC) and swallowing complaints at baseline
were associated to patient reported choking at both time-points.
Conclusions: Three separate risk groups for late aspiration, and two risk groups for late patient-reported
choking were identified based on number of risk factors. The size of the electively treated volume could
be used as a surrogate for individual OARs predicting late aspiration.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xxx (2016) xxx–xxx
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nd/4.0/).Since the introduction of three-dimensional conformal radio-
therapy (3DCRT) and later intensity-modulated radiotherapy
(IMRT) the frequency and severity of xerostomia in head and neck
cancer (HNC) patients has been reduced, mainly through parotid
gland sparing [1]. In contrast, dysphagia remains a significant
long-term side effect with a major impact on patients’ quality of
life (QoL) after definitive radiotherapy (RT) [2]. Treatment intensi-
fications to improve local control and survival with concomitant
chemotherapy and altered fractionation schedules have further
increased post-RT dysphagia [3–5].
As for xerostomia and the parotid glands, there are several pub-
lications on dose–volume relationships between organs at risk
(OARs) and dysphagia [6–11]. However, the anatomical location
of these OARs, often inside the tumour planning target volume
(PTVtumour) or elective planning target volume (PTVelective), makesthem difficult to spare even with known dosimetric constraints
and highly conformal treatment. The PTVtumour cannot be compro-
mised so as not to jeopardise tumour control, but for the PTVelective,
the benefits of treatment, i.e. reduced risk of recurrence, are to be
weighed against the risk of side effects. Efforts have been made at
swallowing-sparing IMRT with modified elective target volumes or
with a lower prescribed elective dose with promising results [12–
14]. Proton therapy might also be useful to further reduce swal-
lowing dysfunction [15].
In addition to dose–volume descriptors, several patient and
treatment-related factors have been reported to be prognostic for
dysphagia, but they are not always taken into account when dose–
response relationships for RT-induced dysphagia are derived [5,16].
ARTSCAN is a Swedish multicentre, randomised, controlled
study of accelerated RT in HNC including 750 patients from twelve
trial centres with published results on locoregional control, overall
survival, QoL, and in depth analyses of several side effects [17–23].
In the ARTSCAN database, patient and treatment characteristics,
longitudinal QoL-data and DICOM-RT data were prospectively col-
lected and stored for future analysis.ARTS-
2 Dysphagia – NTCP from ARTSCANThe primary aim of this study was to evaluate the
potential dose–response relationships of swallowing-related OARs
(SWOARs) and late dysphagia with multivariable normal tissue
complication probability (NTCP) modelling. Two specific endpoints
were chosen: objectively assessed aspiration and patient-reported
choking. A second aim was to study the impact of the size of the
treated elective volume (TVelective) on late objective aspiration.Methods
Patients
All patients alive and free of recurrence treated at two (Umeå
University Hospital, Skåne University Hospital) of the twelve cen-
tres participating in ARTSCAN were invited to a videofluoroscopic
examination (VF) of the swallowing function at a minimum of fif-
teen months after the last inclusion. The two sites had contributed
372 patients to the ARTSCAN study and 185 of them were alive and
free of recurrence and therefore invited to the VF and 124 patients
signed informed consent. Of these, 107 were eligible for VF and 114
for QoL assessment. Aspiration and self-reported problems with
choking could not be evaluated in four patients, since two were
laryngectomised, one tracheotomised and one had a severe stric-
ture in the upper oesophagus and was unable to swallow. In addi-
tion, one patient from the VF cohort and two patients from the QoL
cohort had missing DICOM-RT files. One from the VF cohort and
two from the QoL cohort were excluded due to stroke. Eight
patients were unable to attend and three patients died prior to
the VF. Two of the latter patients were also excluded from QoL
assessment due to second malignancies.
The study was approved by the Regional Ethics Board in Umeå,
Sweden (EPN Umeå Dnr 07-023M).Treatment
The set-up of the ARTSCAN study, details concerning the RT, and
the quality assurance within the trial, have been previously
described in detail [24,25]. In brief, all patients included were ran-
domised to either conventional fractionation (CFx) RT with a total
treatment time of 7 weeks (2 Gy/fraction to a total dose of 68 Gy,
5 days/week) or accelerated fractionation (AFx) RT delivered with
a concomitant boost technique with a total treatment time of
4.5 weeks (2.0 Gy/fraction to 46 Gy, 5 days/week and an additional
daily boost of 1.1 Gy/fraction to 68 Gy) to PTVtumour. The extent of
the PTVelective was not specified in the study protocol and there was
no clear national or international consensus on which lymph node
levels to treat electively at the time of the ARTSCAN study. As a
result there was substantial variation in the elective target vol-
umes with bilateral, unilateral, and selective (not including all of
the lymph-node levels of the neck) elective RT prescribed [24].
The majority of the patients received CT-based 3DCRT (92%) and
the remaining patients received IMRT. Dose prescription and
reporting were made according to the International Commission
on Radiation Units (ICRU) [26,27]. No chemotherapy, neither
neo-adjuvant nor concomitant, was allowed as part of the primary
treatment, and no surgery other than diagnostic, was allowed prior
to RT. Neck dissection (ND) post RT was allowed and utilised,
either as pre-planned or salvage ND when residual disease was
suspected at evaluation after RT, according to local practice at
the participating centres.Videofluoroscopic examination
VF was employed for objective assessment of the swallowing
function. The patients were positioned in an upright posture com-
fortable for swallowing. The swallowing function was examined inPlease cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0frontal and lateral projections. The patients swallowed a 7 ml liq-
uid bolus consisting of barium sulphate, or in case of symptoms
or risk of excessive aspiration, iodine contrast media. If no exten-
sive aspiration was found during the first swallow, the patients
swallowed additional boluses. Aspiration was registered if any
bolus passed below the vocal cords entering the subglottal region,
before, during or after swallowing [28]. The assessments were per-
formed blinded to information on treatment arm (AFx or CFx). One
radiologist and one of two ear- nose, and throat (ENT)-physicians
evaluated each VF. In case of disagreement consensus was reached
through discussion.Endpoints
The primary endpoint for this study was late objective aspira-
tion assessed by VF. The secondary endpoint was patient-
reported late problems with choking, registered prospectively at
baseline, 12 and 60 months after the start of RT with the EORTC
Quality of Life Module for Head and Neck Cancer, EORTC QLQ
H&N 35. We specifically investigated question number 38 (Q38):
‘‘During the past week: Have you choked when swallowing?”. The
question is graded on an ordinal scale from 1 to 4 where 1 = not
at all, 2 = a little, 3 = quite a bit, and 4 = very much. For the analysis,
Q38 was dichotomised in no/minor (1–2) and moderate/severe
(3–4) complaints, respectively.Swallowing organs at risk
Since our primary endpoint was aspiration, we limited the
number of SWOARs to pharyngeal and laryngeal structures: the
superior (SPC), middle (MPC) and inferior (IPC) pharyngeal con-
strictor, the base of tongue (BoT) and, the supraglottic (SGL) and
glottic larynx (GL). We also analysed the merged structures of
the pharyngeal constrictors and larynx as individual SWOARS.
The original CT images from the cohort’s RT data were restored
from the ARTSCAN DICOM database to the treatment planning sys-
tem (Oncentra, Elekta, Sweden), and a systematic delineation of
the SWOARs according to Christianen et al. [29] was performed
by one of the authors (KS). Dose–volume data for the chosen struc-
tures were derived from these updated DICOM-RT structure files
and the original DICOM-RT dose files using the software package
RT Bench (Cureos AB, Uppsala, Sweden).Statistical methods and NTCP modelling
Univariable and multivariable analyses were performed to
describe the association between baseline patient and treatment
characteristics as well as dose–volume descriptors for all SWOARs
and late dysphagia. All parameters significant or borderline signif-
icant (p < 0.1) in univariate analysis were candidates for the multi-
variate NTCP modelling. Odds ratios (OR) together with 95%
confidence intervals were derived from univariable logistic regres-
sion models.
Before carrying out the multivariate logistic regression models
to be used for NTCP-estimation, a stepwise selection of model
parameters was performed. The correlations between candidate
explanatory variables were calculated with Pearson product-
moment correlation. The calculation of the correlations was
restricted to clinical parameters and dose–volume descriptors for
individual and merged SWOARs separately. If a correlation coeffi-
cient rP 0.8 was found between candidate variables, only the vari-
able with the highest univariable association with the outcome
was chosen to enable a sufficient precision of parameter-specific
NTCP functions. To include at least one of the SWOARs in the
model was prioritised.ultivariable predictive modelling on aspiration from a subset of the ARTS-
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values from logistic regression models. In order to identify the
set of variables that was likely to be the best predictor of dyspha-
gia, automated variable selection based on the Bayesian informa-
tion criterion (BIC) was used. The BIC was preferred above the
Akaike’s Information Criterion (AIC) because BIC could be expected
to favour a simpler model. The automated selection algorithm was
based on both backward and forward selection and the final model
was the one that resulted in the optimal model, i.e. the model with
the lowest BIC.
The performance of the final model was assessed by calculating
the area under the curve (AUC) based on the receiver operating
characteristics.
Predictions (NTCP values) derived from final logistic regression
models were performed for each patient and combination of
explanatory parameters, i.e.
NTCP ¼ 1ð1þ eSÞ ; where S ¼ b0 þ
Xn
i¼1
bi  xi
and x1, x2, . . ., xn represent the different input variables and b0, b1,
. . ., bn are the corresponding regression coefficients.
To assess how the results would generalize to an independent
data set, 10-fold data cross-validations of the AUC-estimates were
performed. In 10-fold cross-validation, the data are initially
divided into 10 folds (parts) with one part set aside as a ‘‘test set”.
The AUC, based on the selected model, is calculated from the nine
remaining parts, while one part is used to validate its performance;
this calculation is repeated nine times such that every portion is
used to assess performance, which is ultimately averaged. Bias cor-
rected and accelerated (BCa) confidence intervals were estimated
by bootstrapping the data and repeating the cross-validation
1000 times.
All tests were two-sided and a p-value <0.05 was considered
statistically significant.
Data were analysed with the statistical software package R (ver-
sion 3.1.1; R Development Core Team, R foundation for Statistical
Computing, Vienna, Austria).
Results
Patient and treatment characteristics at baseline for all patients
eligible for either VF or QoL evaluation are shown in Table 1. Global
swallowing function (HNSW), calculated from the swallowing
symptom scale from the patients’ QoL registration prior to RT, is
presented in Table 1 as a measure of baseline dysphagia [30]. Fur-
ther, treated elective volume (TVelective) defined as the difference
between the volumes encompassed by the 95% isodoses of the pre-
scribed elective dose (46 Gy) and the prescribed tumour dose
(68 Gy), is presented as a baseline treatment characteristic
(Table 1).
All tested VD and DV dose–volume descriptors showed a strong
correlation to the mean dose and none of them performed better
than the mean dose in the univariable analyses. Considering these
factors, and to facilitate comparisons with other publications and
clinical interpretation of the results, the mean dose was chosen
for all dose–response NTCP modelling. The distribution of mean
dose in the SWOARs for late aspiration is presented in Fig. 1.
In the NTCP analyses, age at randomisation in the ARTSCAN trial
and global swallowing function at baseline (HNSWB) were dichot-
omised. The cut-off value for age was set at the median age of the
cohort, 56 years (655 vs. >55). For HNSWB we chose HNSWB = 0 vs.
HNSWB > 0 as a majority of the cohort (57%) had a score of zero at
baseline.
The impact of dose per fraction was tested by converting the
physical dose distribution (voxel by voxel) in the patients to equiv-Please cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0alent dose at 2 Gy (EQD2) for late complications assuming
a/b = 3 Gy (EQD23). No significant differences were found in the
results of the NTCP analyses whether EQD23 or physical dose
was applied for the different SWOARs. Therefore, we used physical
dose for all NTCP analyses.
All statistically significant univariable dose–volume relation-
ships between investigated patient or treatment factors and
SWOARs are shown in Table 2. For the parameters entered in the
resulting NTCP model, the multivariate results are shown in
Table 3.Aspiration
The VF took place at a median of 67 (range 25–130) months
after the start of RT. Aspiration was found in 50 (47%) of the 107
eligible patients and 33/50 aspirating patients did not try to pro-
tect their airway by coughing during the examination. Thirteen
of the patients with aspiration had missing data on coughing in
connection with aspiration, and in five patients the aspiration eli-
cited coughing, leading to a total frequency of silent aspiration of
35% (33/95) among all examined patients.
For aspiration, the mean dose to the MPC (Dmean,MPC), age at ran-
domisation (AGE), and ND were included in the NTCP model after
stepwise selection. The cross-validated AUC for the final model was
0.73. Three risk groups were identified: (I) the low-risk group
included patients with neither of the risk factors (ND post RT or
AGE >55 years), (II) the intermediate group included patients with
one of the two risk factors, and (III) the high-risk group included
patients with both identified risk factors.
A graphical representation of NTCPASP vs. Dmean,MPC is presented
in Fig. 2.Patient-reported choking
Of the 114 eligible patients, 111 completed Q38 in the QLQ H&N
35 at baseline. None of the patients reported severe problems with
choking at baseline, and 4.5% (5/111) reported moderate problems.
106 completed Q38 in the QLQ H&N 35 inventory at one year post
RT and 98/114 at five years. The prevalence of patient-reported
moderate/severe choking when swallowing was 25.5% (27/106)
at one year post RT and 28.6% (28/98) at five years. The univariable
results of Q38 are presented in Table 2. Multivariable analysis
resulted in the same variables, Dmean,SPC and HNSWB, for the NTCP
models at both time points. Two risk groups for moderate/severe
problems with choking were identified: (I) the low-risk group with
HNSWB = 0, and (II) the high-risk group with HNSWB > 0. The
model performance for the one-year result was modest (cross-
validated AUC = 0.66), while the NTCP model based on the five-
years results performed better (cross-validated AUC = 0.78) (Fig. 3).TVelective
The impact of the size of the treated elective volume, TVelective,
for development of late objective aspiration was investigated.
The correlation between TVelective and clinical parameters such as
T- and N-stage was low (correlation coefficient r < 0.4). In contrast,
TVelective correlated strongly to the mean dose in all SWOARs (>0.6)
except SPC (0.4) and BoT (0.3). Since neither SPC nor BoT was sig-
nificant in the univariable analysis of the primary endpoint, AGE,
ND and HNSWB were the only variables considered in addition to
TVelective for the multivariable modelling.
The resulting model, predicting late aspiration, derived the
same risk factors as the model based on Dmean,MPC, AGE and ND,
with a cross-validated AUC of 0.74 (Fig. 4).ultivariable predictive modelling on aspiration from a subset of the ARTS-
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Table 1
Patient, clinical and treatment characteristics.
Characteristics Endpoint: QoL Endpoint: ASP
N = 114 (%) N = 107 (%)
Gender
Male 87 (75.4) 81 (74.7)
Female 28 (24.6) 27 (25.3)
Age at randomisation (y)
<55 48 (42.1) 45 (42.0)
P55 66 (57.9) 62 (58.0)
Primary tumour site
Oral cavity 23 (20.2) 23 (21.5)
Oropharynx 69 (60.5) 63 (58.9)
Hypopharynx 9 (7.9) 9 (8.4)
Larynx 13 (11.4) 12 (11.2)
Tumour classification*
T1 23 (20.2) 21 (19.6)
T2 51 (44.7) 50 (46.7)
T3 24 (21.1) 22 (20.6)
T4 16 (14.0) 14 (13.1)
Nodal classification*
N0 46 (40.4) 43 (40.2)
N1 21 (18.4) 21 (19.6)
N2a 18 (15.8) 17 (15.9)
N2b 18 (15.8) 16 (15.0)
N2c 4 (3.5) 4 (3.7)
N3 7 (6.1) 6 (5.6)
Fractionation (fx) schedule
AFx 64 (56.1) 60 (56.1)
CFx 50 (43.9) 47 (43.9)
Neck dissection (ND)
Yes 50 (43.9) 47 (43.9)
No 64 (56.1) 60 (56.1)
Global swallowing function at baseline (HNSW)
0 65 (57.0) 61 (57.0)
>0 47 (41.2) 44 (41.1)
Missing 2 (1.8) 2 (1.9)
Current smoker (at start of RT)
Yes 20 (17.5) 19 (17.8)
No 73 (64.0) 67 (62.6)
Missing 21 (18.4) 21 (19.6)
Treated elective volume (TVelective) (cm3)
All patients
Mean 785 759
Median 687 684
Unilateral treatment (36% of the patients, VF and QoL)
Mean 377 380
Median 388 372
Bilateral treatment (63% of the patients, VF and QoL)
Mean 991 1021
Median 969 990
* TNM classification, UICC, Geneva, 1987.
4 Dysphagia – NTCP from ARTSCANDiscussion
Our primary objective with this study was to evaluate the dose–
volume relationships of aspiration and established SWOARs
together with other known prognostic factors for dysphagia using
multivariate NTCP modelling. Our multivariate model for predict-
ing late aspiration included mean dose to the MPC, age at randomi-
sation in the ARTSCAN trial, and neck dissection post RT. Age is an
often investigated and reported risk factor for dysphagia, though
there are reports without an established relation to swallowing
problems [5,6]. In contrast, the impact of ND on late aspiration
has been rarely reported. In the present material, Lindblom et al.
have previously reported ND post RT to be an independent risk fac-
tor for late aspiration [23]. In concordance with our findings,
Machtay et al. demonstrated ND as a strong independent risk fac-
tor for late dysphagia in a large material of Radiation Therapy
Oncology Group (RTOG) studies [3]. Caudell et al. [6] and Levendag
et al. [9] reported on the prevalence of ND but not on its impact on
dysphagia.Please cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0In the present study, three risk groups for late aspiration could
be identified. The risk of late aspiration at Dmean,MPC = 50 Gy (the
mean dose constraint recommended by Quantec to pharynx as a
whole) was approximately 10% in the low-risk group (I), nearly
30% in the intermediate group (II), and over 65% in the high-risk
group (III).
As secondary endpoints, we investigated patient-reported mod-
erate/severe complaints with choking assessed prospectively by
the EORTC QLQ H&N 35 inventory at one and five-years post RT
with multivariate NTCP modelling. The frequency of patients with
moderate/severe complaints at both time points was similar (25.5%
at 12 months and 28.6% at 60 months). Thus, our study could not
verify the hypothesis of a response shift, a process in which
patients adapt to side effects in time with a subsequent shift of
the NTCP curve to the right over time in patient-reported com-
plaints [31].
For patient reported moderate/severe problems with choking,
the multivariate NTCP models both identified two risk groups
based on global swallowing function at baseline and Dmean,SPC.ultivariable predictive modelling on aspiration from a subset of the ARTS-
01
Fig. 1. Box-plot of mean dose distribution in SWOARs for patients with or without
aspiration. Mean dose in the different structures. Boxes represent the 25th and 75th
quartiles and the dots represent outliers. The line in the boxes represents the
median of mean doses in each structure. Abbreviations: BoT = base of tongue;
GL = glottic larynx; IPC = inferior pharyngeal constrictor; MPC = middle pharyngeal
constrictor; PC = pharyngeal constrictors; SGL = supra glottic larynx; SPC = superior
pharyngeal constrictor.
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naire at 12 months was poor, and the resulting dose–response
curve had a small dose gradient making it less useful in clinical set-
tings. The model based on the questionnaire collected at
60 months post RT had a good performance and a steeper NTCP
curve. For the low-risk group (I) without swallowing complaints
at baseline, Dmean,SPC as high as 60 Gy produced relatively few late
moderate/severe problems with choking (<10%). For the high-risk
group (II), an increase of 15% in risk for each additional 10 Gy in
Dmean,SPC was seen already at Dmean,SPC >30 Gy. Although the model
predicting patient-reported choking at one-year was poor, the
robustness of the parameters established in the models is sup-
ported by the same parameters derived at both 12 and 60 months
in the multivariable analysis. For patient-rated problems withTable 2
Univariable correlations between endpoint and investigated parameter. Results from univ
Parameter OR 95% CI p-value OR
Endpoint: ASP Endpo
Age at rand (655 vs >55) 2.74 1.24–6.20 0.014⁄ 1.33
Age at rand 1.04 0.10–1.08 0.088⁄ 1.01
Gender (female vs male) 0.61 0.25–1.48 0.268 0.49
Oropharynx vs other 0.73 0.33–1.60 0.427 0.63
T-stage (3–4 vs 1–2) 1.97 0.86–4.61 0.111 1.17
N-stage (1–3 vs 0) 1.65 0.74–3.73 0.222 1.47
AFx 1.88 0.86–4.22 0.118 0.42
Neck dissection, ND 3.75 1.68–8.69 0.002⁄ 1.21
HNSW (>0 vs 0) 1.09 0.51–2.41 0.794 2.68
Current smoker 0.75 0.26–2.10 0.575 1.24
Dmean,MPC 1.06 1.01–1.11 0.016⁄ 1.03
Dmean,IPC 1.03 1.01–1.05 0.024⁄ 1.02
Dmean,SPC 1.02 0.10–1.05 0.252 1.05
Dmean,IPC+MPC+SPC 1.04 1.00–1.08 0.046⁄ 1.05
Dmean,GL 1.02 1.00–1.04 0.022⁄ 1.01
Dmean,SGL 1.03 0.10–1.05 0.088⁄ 1.03
Dmean,GL+SGL 1.03 1.00–1.05 0.045⁄ 1.02
Dmean,BOT 1.02 0.98–1.06 0.448 1.05
TVelective 1.00 1.001–1.003 0.001⁄ 1.00
Please cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0choking collected by the EORTC QLQ-H&N 35 questionnaire, Chris-
tianen et al. [7] obtained their best performance with a model
including the SGL and the oesophageal inlet muscles using the
same definition of SWOARs as the present study. However, in their
study the QoL questionnaire was collected at six months post RT,
thus reflecting acute side effects rather than late [7].
Our study, as well as others, has suggested that a high dose to
the upper pharyngeal region has the highest impact on the devel-
opment of late dysphagia, while the impact of a high dose to laryn-
geal structures seems to decline over time [32,33].
Disturbed sensibility of the pharynx/larynx post (chemo)-RT
may cause patients to underestimate swallowing problems that
can be demonstrated with VF [34]. This is supported by our results,
where the frequency of moderate/severe self-reported choking was
lower than that of aspiration on VF, and the majority of the aspira-
tion was silent.
To quantify the impact of electively treated volume on late dys-
phagia, we present an NTCP model for aspiration based on TVelective
as a simpler alternative to a model based on delineated anatomical
structures. To exemplify the risk for late objective dysphagia, we
use the median TVelective in the present study (0.68 litre). For a
patient in the low-risk group without ND post RT and 655 years
at randomisation (I), the risk of late aspiration was below 20%,
approximately 40% for the intermediate-risk group (II) and over
70% risk of late aspiration in the high-risk group (III). It is impor-
tant to consider that this material mainly consists of patients trea-
ted with 3DCRT. The use of more recent therapy techniques may
result in smaller treated volumes.
Inconsistent results of the impact of IMRT on dysphagia mea-
sured with the EORTC QLQ-H&N 35 module have been published
[7,11,35]. Data from a treatment simulation study of IMRT aimed
at reducing NTCP for dysphagia suggests that in a majority of the
cases, this comes at the expense of increased NTCP for xerostomia
[36].
No chemotherapy was used in the present study, and the NTCP
models are therefore not applicable to chemo-RT. The addition of
chemotherapy to the RT is of major importance for the develop-
ment of late dysphagia [2]. Data on sole RT effects on late dyspha-
gia are sparse and the present study may be useful for future
comparison of the additional adverse effect of combined
treatments.
Limitations in the present study include the lack of VF at base-
line and the cross sectional collection of the VFs. However, only 5ariable logistic regression.
95% CI p-value OR 95% CI p-value
int: Q38 at 1 year Endpoint: Q38 at 5 year
0.54–3.32 0.535 1.65 0.66–4.24 0.288
0.97–1.05 0.719 1.00 0.96–1.05 0.893
0.13–1.45 0.228 0.85 0.28–2.36 0.764
0.23–1.58 0.331 0.43 0.15–1.11 0.090⁄
0.44–2.96 0.745 1.80 0.70–4.59 0.220
0.49–3.06 0.695 2.72 1.02–8.19 0.057⁄
0.17–1.03 0.060⁄ 0.39 0.15–0.98 0.046⁄
0.49–2.96 0.682 1.46 0.59–3.66 0.410
1.09–6.79 0.034⁄ 5.80 2.21–16.78 0.001⁄
0.38–4.83 0.735 1.61 0.45–7.70 0.498
0.98–1.09 0.222 1.04 0.99–1.11 0.128
0.99–1.05 0.213 1.01 0.99–1.04 0.433
1.01–1.10 0.040⁄ 1.06 1.02–1.12 0.013⁄
1.01–1.11 0.045⁄ 1.07 1.02–1.14 0.012⁄
0.99–1.04 0.239 1.01 0.99–1.03 0.580
0.10–1.07 0.122 1.01 0.98–1.05 0.510
0.99–1.05 0.159 1.01 0.99–1.04 0.425
0.10–1.13 0.114 1.08 1.02–1.19 0.040⁄
1.000–1.002 0.065⁄ 1.00 1.000–1.003 0.021⁄
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Table 3
Predictive parameters from multivariable logistic regression analyses for the final NTCP models. Results from multivariable logistic regression, only the parameters selected in the
final NTCP modelling are presented.
Predictor Coefficient Adjusted OR 95% CI p-value
Endpoint: Aspiration
Age at randomisation (>55 vs 655) 1.372 3.94 1.63–10.21 0.003
Neck dissection, ND 1.314 3.72 1.56–9.31 0.004
Dmean,MPC 0.062 1.07 1.01–1.12 0.015
Constant 5.195
(ROC AUC = 0.73 [95% CI 0.58–0.81])
Endpoint: Q38 at 1 year
HNSW (>0 vs 0) 1.113 3.04 1.22–7.94 0.019
Dmean,SPC 0.049 1.05 1.01–1.11 0.033
Constant 4.441
(ROC AUC = 0.66 [95% CI 0.46–0.78])
Endpoint: Q38 at 5 years
HNSW (>0 vs 0) 2.105 8.21 2.80–24.08 0.001
Dmean,SPC 0.084 1.09 1.03–1.16 0.004
Constant 7.012
(ROC AUC = 0.78 [95% CI 0.66–0.85])
Endpoint: Aspiration based on TVelective
Age at randomisation (>55 vs 655) 1.275 3.58 1.48–9.25 0.006
Neck dissection, ND 1.049 2.86 1.13–7.42 0.028
TVelective 0.002 1.00 1.001–1.003 0.007
Constant 2.553
(ROC AUC = 0.74 [95% CI 0.61–0.82])
Fig. 2. Normal tissue complication probability for aspiration. NTCP-curve for
aspiration based on mean dose in the middle pharyngeal constrictor (MPC). (I) No
risk factors, (II) one of the risk factors, and (III) both risk factors. The individual risk
factors are indicated as follows: black line = age > 55 years, and grey line = 6 55 -
years of age at randomisation in the ARTSCAN-study; solid line = neck dissection
(ND) post RT, and broken line = no ND.
Fig. 3. Normal tissue complication probability for patient-reported problems with
choking at 60 months post RT. NTCP-curve for aspiration based on mean dose in the
superior pharyngeal constrictor (SPC). Global swallowing function at baseline
(HNSWB), is indicated as follows: broken line = HNSWB = 0, solid line = HNSWB > 0.
6 Dysphagia – NTCP from ARTSCAN(4.5%) patients reported moderate problems with choking at base-
line and none reported severe problems to Q38. The known post-
treatment complication with deteriorated sensibility that can lead
to difficulties for the patients to recognise their aspiration symp-
toms, should not be an issue for identifying subjective symptoms
prior to RT, and we conclude that patients with pre-treatment aspi-
ration would presumably all report symptoms. Feng et al. [37],
reported that 3/33 (8%) patients showed aspiration in the VF-
examination prior to treatment of H&N cancer with a significant
increase to 44% three month after IMRT. The post-treatment result
is in accordance with ours. It is also known that pre-treatmentPlease cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0aspiration can improve post-treatment in patients with laryngeal
cancer [14,38], meaning that pre-treatment aspiration might not
always persist after RT. Only eight patients in the present study
had laryngeal cancer with a T-stage >2.
The frequency of aspiration after (chemo)-RT is reported to sta-
bilise after one year, and no VF in the present study was performed
earlier than 25 months after RT was initiated [14].
Comparisons between studies regarding dysphagia post RT are
difficult because there is no gold standard to describe or quantify
the problem. A substantial discrepancy between subjective (i.e.
physician or patient-rated toxicity scores) and objective (i.e. VF)
ratings has been reported [39]. Moreover, they reflect somewhat
different sides of the problem. Hence, until a gold standard forultivariable predictive modelling on aspiration from a subset of the ARTS-
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Fig. 4. Normal tissue complication probability for aspiration based on electively
treated volume. NTCP curve for aspiration based on TVelective. (I) No risk factors, (II)
one of the risk factors and (III) both risk factors. The individual risk factors are
indicated as follows: black line = age > 55 years, and grey line = 6 55 years of age at
randomisation in the ARTSCAN study; solid line = neck dissection (ND) post RT, and
broken line = no ND.
K. Söderström et al. / Radiotherapy and Oncology xxx (2016) xxx–xxx 7reporting dysphagia is established, both validated objective and
subjective methods should be used. In the present study, both
objective and patient-rated measures are presented. To facilitate
the interpretability, we have used a publicly available, published
contouring atlas in the delineations of the SWOARs [29].
The NTCPs presented in the present study are multifactorial and
include prospectively collected clinical prognostic factors for dys-
phagia. The results suggest that the clinical factors are of utmost
importance in predicting late dysphagia together with dose–vol-
ume parameters.
Elective bilateral RT is a known prognostic factor for dysphagia
[5,7]. A more precise measure of radiation burden might be the
treated volume. This allows for evaluation of selective treatment,
not treating all the lymph nodes of the neck, a concept frequently
used in the ARTSCAN study. The use of treated volume might also,
at least in part, compensate for the less conformal dose distribution
with 3DCRT than with IMRT. As one of our objectives was to eval-
uate the risk of late aspiration correlated to the electively treated
volume (TVelective), multivariate NTCP modelling for TVelective was
performed separately, using the same methodology as for the other
predictive models. As suspected, TVelective was predictive of aspira-
tion, confirming that not only the dose in individual SWOARs but
also the size of the treatment volume is predictive for the develop-
ment of dysphagia.
To our knowledge, the only previous study on NTCP for the out-
come of late aspiration measured with VF by Eisbruch et al. pre-
sented a significant correlation to the pharyngeal constrictors
[12]. Their best performing model was for the pharyngeal constric-
tors combined, and when analysed separately, SPC displayed the
strongest correlation. Our study showed no significant correlation
between aspiration and the SPC, but significant results were found
in both uni- and multivariable analyses for the MPC, IPC and the
merged structure of all pharyngeal constrictors. Different dose dis-
tributions, which might depend on differences in delineation,
tumour site and RT techniques, could contribute to varying results
between publications regarding which SWOAR has the strongest
correlation to the outcome. The SWOAR selected in our NTCP
model is perhaps not surprising, when considering the distribution
of mean dose in the SWOARs between patients with and withoutPlease cite this article in press as: Söderström K et al. Dysphagia – Results fromm
CAN trial. Radiother Oncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.09.0aspiration respectively presented in (Fig. 1). Both this and other
studies have shown a strong internal correlation between the dif-
ferent SWOARs [12]. Considering this, it might be appropriate to
look at the dose in multiple SWOARs instead of a single SWOAR.
In the present study, however, the predictive value of the com-
bined SWOARs for late aspiration had a weaker correlation than
that of the MPC for aspiration at VF. A simpler method than delin-
eating individual SWOARs proposed in the present study might be
to consider the treated volume.
Conclusions
Three risk groups for late aspiration were identified based on
mean dose to the MPC, age and neck dissection. With a mean dose
to the MPC of 50 Gy, the risk of late aspiration in the high-risk
group was over 65%. Our model for risk of late patient-reported
choking identifies swallowing complaints at baseline and mean
dose to the SPC as risk factors.
In addition, we present a multivariate NTCP model for late aspi-
ration based on electively treated volume, indicating that the size
of the treated volume, not only dose to the SWOARs, are predictive
of late dysphagia.
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